Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTORPHANOL TARTRATE vs ALOGLIPTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Management of moderate to severe pain,Preoperative medication,Supplement to balanced anesthesia,Relief of pain during labor,Off-label: Migraine headache (via intranasal route)
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus,Combination therapy with metformin, sulfonylurea, thiazolidinedione, or insulin
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
25 mg orally once daily
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Butorphanol is extensively metabolized in the liver via hydroxylation and N-dealkylation, primarily by CYP3A4. The major metabolite is hydroxybutorphanol, which has some analgesic activity but is less potent.
Alogliptin is minimally metabolized; approximately 60-70% excreted unchanged in urine. Metabolism involves hepatic microsomal enzymes, primarily CYP2D6 and CYP3A4, but to a minor extent.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Approximately 80% bound to plasma proteins (mainly alpha-1-acid glycoprotein and albumin).
20% bound to plasma proteins, primarily albumin. Binding is concentration-independent.
Vd: 4-5 L/kg (range 3-6 L/kg), indicating extensive tissue distribution, including CNS.
Volume of distribution is approximately 33 L (0.47 L/kg assuming 70 kg). This suggests distribution into total body water, but not extensive tissue binding.
Intranasal: 60-70% (range 48-80%); IM: 80-100% (complete but variable); Oral: very low (<5%) due to extensive first-pass metabolism; not used orally.
Oral bioavailability is approximately 100%, indicating complete absorption with minimal first-pass metabolism.
No specific guidelines for dose adjustment in renal impairment; use with caution. For severe renal impairment (e GFR <30 m L/min), consider reducing dose and/or extending dosing interval due to potential accumulation of active metabolites.
e GFR 30-59 m L/min: 12.5 mg orally once daily; e GFR 15-29 m L/min: 6.25 mg orally once daily; e GFR <15 m L/min or dialysis: 6.25 mg orally once daily
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50% and monitor for excessive sedation. Class C: Avoid use or reduce dose to 25% of normal and monitor closely.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B); not recommended for severe hepatic impairment (Child-Pugh C)
Weight-based: 0.01-0.02 mg/kg intravenously or intramuscularly every 3-4 hours as needed; maximum single dose 1 mg. For intranasal: 1 mg as a single dose in patients ≥18 kg (for migraine). Not recommended for PCA in children.
Safety and efficacy not established; no recommended dosing available
Reduce initial dose by 50% (e.g., 0.5-1 mg IV/IM every 4-6 hours); titrate cautiously due to increased sensitivity to opioid effects and risk of respiratory depression. For intranasal, consider lower dose (0.5 mg). Monitor renal function.
No dose adjustment recommended based on age alone; monitor renal function and adjust dose accordingly
Concomitant use of opioids with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
None.
Respiratory depression: especially in patients with compromised respiratory function or when used with other CNS depressants,Dependence and abuse liability: Schedule IV controlled substance,Increases in intracranial pressure: may exacerbate in patients with head injury,Cardiovascular effects: may increase cardiac workload and should be avoided in acute MI,Biliary tract spasm: may cause spasm of the sphincter of Oddi,Withdrawal: may precipitate withdrawal in opioid-dependent patients if given shortly after other mu-agonists
Pancreatitis: Cases of acute pancreatitis have been reported; discontinue if pancreatitis is suspected.,Hypersensitivity reactions: Including anaphylaxis, angioedema, and severe cutaneous adverse reactions.,Heart failure: Consider risk factors; monitor for signs and symptoms.,Severe and disabling arthralgia has been reported.,Acute renal failure: Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) or end-stage renal disease.,Hypoglycemia when used in combination with insulin or sulfonylureas.
Hypersensitivity to butorphanol tartrate or any component of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Known or suspected gastrointestinal obstruction,Patients who are physically dependent on mu-agonists due to risk of acute withdrawal
History of serious hypersensitivity reaction to alogliptin or any excipient,Type 1 diabetes mellitus,Diabetic ketoacidosis
Avoid alcohol and grapefruit juice (may increase butorphanol levels). No specific food restrictions.
No specific food interactions; can be taken with or without food. Avoid excessive alcohol intake due to potential hypoglycemia risk when used with other agents.
Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis produced increased fetal resorptions and decreased fetal weights at doses 3-6 times the human therapeutic dose. In the first trimester, risks cannot be ruled out. In the second and third trimesters, prolonged use may cause neonatal opioid withdrawal syndrome. Use near term may cause respiratory depression in the neonate.
Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and well-controlled studies in pregnant women exist. Use only if clearly needed. First trimester risk cannot be ruled out; limited human data.
Butorphanol is excreted into human milk. The milk-to-plasma ratio (M/P) is approximately 0.7. Limited data suggest low levels; however, due to potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends avoiding use while breastfeeding.
It is unknown if alogliptin is excreted in human breast milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account importance to the mother.
Pregnancy may alter butorphanol pharmacokinetics due to increased plasma volume and enhanced clearance. However, specific dose adjustment recommendations are not established. Use lowest effective dose for shortest duration. For labor analgesia, standard IV/IM doses (1-2 mg) may be used, but monitor for maternal and neonatal respiratory depression.
No specific dose adjustments recommended; however, pregnancy may alter pharmacokinetics of alogliptin. Avoid use when possible, particularly during the second and third trimesters, due to limited safety data.
Butorphanol is a mixed agonist-antagonist opioid; may precipitate withdrawal in opioid-dependent patients. Ceiling effect on respiratory depression. Higher risk of psychotomimetic effects (dysphoria, hallucinations) compared to morphine. Onset: 1-2 min IV, 5-10 min IM; duration 3-4 hours. Nasal spray has bioavailability ~70%.
Alogliptin is a DPP-4 inhibitor with minimal risk of hypoglycemia when used as monotherapy; dosing adjustments required for renal impairment (creatinine clearance <60 m L/min). Monitor for acute pancreatitis and severe arthralgia. No significant weight loss or gain. Use with caution in patients with history of pancreatitis.
May cause drowsiness or dizziness; avoid driving or operating machinery.,Do not take with alcohol or other CNS depressants.,Can cause nausea, vomiting, or sweating; report severe reactions.,Use exactly as prescribed; risk of dependence with long-term use.,If you are dependent on opioids, this drug may cause withdrawal symptoms.,Notify your doctor if you have a history of head injury, asthma, or liver/kidney disease.
Take alogliptin with or without food once daily.,Do not skip meals, especially if taking other diabetes medications that cause hypoglycemia.,Contact healthcare provider immediately if you experience persistent severe abdominal pain (sign of pancreatitis).,Report any joint pain that is new or worsening.,Store at room temperature away from moisture and heat.
"Butorphanol, a mixed agonist-antagonist opioid, and dimenhydrinate, a histamine H1 antagonist, exhibit additive central nervous system (CNS) depression. Concurrent use increases the risk of profound sedation, respiratory depression, dizziness, and psychomotor impairment. These effects are dose-dependent and can lead to hazardous outcomes such as falls, respiratory compromise, or coma, particularly in elderly or debilitated patients."
"Concomitant use of butorphanol, a mixed agonist-antagonist opioid, with pipotiazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression, including sedation, respiratory depression, and hypotension. Pipotiazine may also potentiate the analgesic effects of butorphanol through antagonism at dopamine D2 receptors, but this combination increases the risk of extrapyramidal symptoms and neuroleptic malignant syndrome. Clinically, patients may experience excessive sedation, confusion, orthostatic hypotension, and impaired psychomotor function."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Sunitinib, a tyrosine kinase inhibitor, may enhance the glucose-lowering effects of alogliptin, a DPP-4 inhibitor, by impairing renal function and potentially reducing the renal clearance of alogliptin, leading to increased exposure and risk of hypoglycemia. This interaction is particularly relevant in patients with pre-existing renal impairment or those receiving high-dose sunitinib. Clinical outcomes include episodes of symptomatic hypoglycemia, which may require dose adjustment of antidiabetic therapy."
"Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, enhancing glucose-dependent insulin secretion. Mesalazine, known for its anti-inflammatory effects in inflammatory bowel disease, may independently lower blood glucose via unknown mechanisms. Concurrent use could potentiate hypoglycemic effects, especially in patients with diabetes or impaired glucose regulation, increasing the risk of symptomatic hypoglycemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTORPHANOL TARTRATE vs ALOGLIPTIN, answered by our medical review team.
BUTORPHANOL TARTRATE is a Opioid Analgesic that works by Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.. ALOGLIPTIN is a DPP-4 Inhibitor that works by Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTORPHANOL TARTRATE and ALOGLIPTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTORPHANOL TARTRATE is: 1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.. The standard adult dose of ALOGLIPTIN is: 25 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTORPHANOL TARTRATE and ALOGLIPTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTORPHANOL TARTRATE is classified as Category C. Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis . ALOGLIPTIN is classified as Category C. Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and we. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.